European stocks retreat; BOE rate decision in focus
Investing.com - European stock markets traded sharply lower Thursday, as investors digested more corporate earnings and key economic data ahead of the Bank of England's latest rate...
Sell
or
Merck News & Analysis
-
-
European stock futures flat; BOE, services PMI, earnings in spotlight
Investing.com - European stock markets are expected to open largely unchanged Thursday, with investors cautious ahead of a Bank of England rate decision, key inflation and services activity...
-
: Merck swings to loss as it books charge on $10.8 billion acquisition of Prometheus Biosciences
Merck's earnings were also hit by lower sales of its COVID antiviral Lagevrio.
-
Merck Swings Into Q2 Loss On Prometheus Biosciences Acquisition Charge, But Raises FY23 Revenue Outlook
Merck & Co Inc's (NYSE: MRK) Q2 sales reached $15.04 billion, up 3% Y/Y, beating the consensus of $14.39 billion. Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding...
-
: Merck posts narrower-than-expected loss and sales top estimates
Merck & Co. Inc. MRK posted a narrower-than-expected loss for the second quarter early Tuesday following its acquisition of Prometheus Bio and sales that topped estimates, despite a steep...
-
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
Shares of Merck are down roughly 4% this year, with a market value of roughly $270 billion, making it the third largest pharmaceutical company based in the U.S.
-
HSBC maintains Merck at 'buy' with a price target of EUR185.00
An analyst from HSBC maintained Merck (ETR: MRCG) at 'buy' with a price target of EUR185.00 from a prior price target of EUR200.00. Prior to this rating, Merck had 14 buy ratings, 3 hold...
-
Merck Releases Encouraging Data From Two Late-Stage Studies For Pneumococcal Conjugate Vaccine
Merck & Co Inc (NYSE: MRK) announced topline results from two Phase 3 trials evaluating V116, the company's investigational 21-valent pneumococcal conjugate vaccine in vaccine-naïve and...
-
Non-small Cell Lung Cancer Market is Projected to Boost by 2032, Predicts DelveInsight | Key Companies Working in Space - AstraZeneca, BMS, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly, Immutep, Sanofi, GlaxoSmithKline
New York, USA, July 27, 2023 (GLOBE NEWSWIRE) -- Non-small Cell Lung Cancer Market is Projected to Boost by 2032, Predicts DelveInsight | Key Companies Working in Space - AstraZeneca,...
-
: Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanoma
Merck & Co. MRK and Moderna Inc. MRNA said Wednesday they have launched a Phase 3 trial of Moderna’s V940 in combination with Merck’s Keytruda as a treatment for patients with high-risk, or...
-
Morgan Stanley maintains Merck at 'overweight' with a price target of EUR197.00
An analyst from Morgan Stanley maintained Merck (ETR: MRCG) at 'overweight' with a price target of EUR197.00 from a prior price target of EUR206.00. Prior to this rating, Merck had 14 buy...
-
Credit Suisse maintains Merck at 'outperform' with a price target of EUR180.00
An analyst from Credit Suisse maintained Merck (ETR: MRCG) at 'outperform' with a price target of EUR180.00 from a prior price target of EUR200.00. Prior to this rating, Merck had 14 buy...
-
Barclays maintains Merck at 'overweight' with a price target of EUR200.00
An analyst from Barclays maintained Merck (ETR: MRCG) at 'overweight' with a price target of EUR200.00 from a prior price target of EUR210.00. Prior to this rating, Merck had 14 buy...
-
Deutsche Bank maintains Merck at 'buy' with a price target of EUR205.00
An analyst from Deutsche Bank maintained Merck (ETR: MRCG) at 'buy' with a price target of EUR205.00 from a prior price target of EUR220.00. Prior to this rating, Merck had 14 buy ratings,...
-
: Johnson & Johnson joins Merck, others, in fighting Medicare drug-price program
Johnson & Johnson JNJ has joined companies such as Merck & Co. Inc. MRK, Bristol Myers Squibb Co. BMY and other entities in suing the federal government over Medicare’s drug-price...
-
Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi, Sentien Biotechnologies, Basilea, Vivacelle Bio, Sanofi, BioAegis, Pharmazz
New York, USA, June 29, 2023 (GLOBE NEWSWIRE) -- Sepsis Market Size and Share to Grow by 2032, Examines DelveInsight | Key Companies Developing Therapies - Regeneron, Merck, Shionogi,...
-
Merck, Ridgeback Withdraw COVID-19 Pill European Application Amid Regulatory Hurdles
Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics have reportedly withdrawn their COVID-19 pill application in the European Union (EU). The withdrawal came after the European...
-
Merck & Co Accused of Underplaying Mental Health Risks from Asthma and Allergy Drug Singulair
Initially, when released in 1998, Merck & Co Inc's (NYSE: MRK) asthma and allergy drug, Singulair, claimed side effects were mild and similar to a placebo, and the label stated that its...
-
JPMorgan maintains Merck at 'overweight' with a price target of EUR220.00
An analyst from JPMorgan maintained Merck (ETR: MRCG) at 'overweight' with a price target of EUR220.00 from a prior price target of EUR225.00. Prior to this rating, Merck had 12 buy...
-
IRBM Extends Peptide Therapeutics Collaboration with Merck & Co. Inc., Rahway NJ USA
ROME, June 22, 2023 (GLOBE NEWSWIRE) -- IRBM, an innovative contract research organization, today announced it has signed a new agreement with Merck & Co. Inc., Rahway NJ USA, known as...
-
Cervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market - Gilead, Roche, Genentech, Iovance, Bristol-Myers Squibb, Exelixis, Xencor, Merck, EMD Serono, Pfizer, Fusion, AstraZeneca
New York, USA, June 22, 2023 (GLOBE NEWSWIRE) -- Cervical Cancer Market Size is Likely to Increase, Examines DelveInsight | Key Companies in the Market - Gilead, Roche, Genentech,...
-
Merck Says Keytruda Regimen Fails To Improve Event-Free Survival In Gastric Cancer Patients
Merck & Co Inc (NYSE: MRK) announced topline results from the Phase 3 KEYNOTE-585 trial of Keytruda (pembrolizumab) in combination with chemotherapy as a neoadjuvant treatment regime. The...
-
Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court
The lawsuits are the opening salvo in a historic and potentially decisive battle over Medicare's efforts to bring rising drug prices under control.
-
Merck's Keytruda Combo Therapy Hits Primary Goal In Patients With Rare Form Of Gastric Cancer
Merck & Co Inc (NYSE: MRK) announced topline data from the Phase 3 KEYNOTE-811 trial of Keytruda (pembrolizumab) plus trastuzumab and chemotherapy for human epidermal growth factor receptor...
-
: Merck says court ruled in its favor over patent-infringement suit
Drugmaker Merck & Co. MRK on Tuesday said that a U.S. district court had validated U.S. patent protection for its neuromuscular drug Bridion through “at least January 2026.” The announcement...
-
BofA Securities maintains Merck at 'buy' with a price target of EUR205.00
An analyst from BofA Securities maintained Merck (ETR: MRCG) at 'buy' with a price target of EUR205.00. Prior to this rating, Merck had 13 buy ratings, 3 hold ratings, and 0 sell...
-
: White House signals no pause on Medicare drug price negotiations after Merck lawsuit
Administration officials highlight Inflation Reduction Act prescription-drug savings as negotiation process moves forward.
-
: Merck is suing the government over Medicare drug prices—what retirees need to know
Inflation Reduction Act provision was set to lower drug costs for millions of retirees
-
: Merck lawsuit challenging Medicare drug price negotiation signals long battle ahead, experts say
Pharmaceutical giant says it's prepared to take case to the Supreme Court as it seeks to sidestep negotiation program
-
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
